1. Scrip
  2. >>Business
  3. >>Strategy

Blueprint Medicines: A New Twist On Kinase Discovery

 
• By Michael Goodman

The convergence of maturing technology, growing industry demand for combination therapy, and regulatory innovation have given rise to Blueprint Medicines, a pure-play kinase specialist that aspires to become a US-focused cancer company.

Historically, few biopharms have focused on kinase R&D. Sugen Inc., the granddaddy of them all, generated all its considerable value well over a decade after it was acquired by Pharmacia Corp. and then Pfizer Inc. in the form of the cancer drugs Sutent (sunitinib) and Xalkori (crizotinib). In recent years, some small companies have had success: Pharmacyclics Inc. with Imbruvica (ibrutinib, a BTK inhibitor) or Incyte Corp. with Jakafi (ruxolitinib, a JAK inhibitor). But none have been wholly dedicated to kinase R&D from its founding, until recently.

Blueprint Medicines Corp. was incubated and launched by Third Rock Ventures in 2011 along with a $40 million Series...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

More from Business

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.